NNIT A/S: 14/2015 Major shareholder announcement

Company announcement 14/2015 Søborg/Copenhagen, 26 March 2015 Major shareholder announcement With reference to announcement no. 8 dated 6 March 2015 regarding major shareholder notification and announcement no. 12 dated 26 March 2015 regarding exercise of the overallotment option in connection with the initial public offering of shares in NNIT A/S (the "Overallotment Option"), NNIT A/S ("NNIT") hereby announces the receipt of the following notification pursuant to...

Company announcement 14/2015

Søborg/Copenhagen, 26 March 2015

 

 

Major shareholder announcement

 

With reference to announcement no. 8 dated 6 March 2015 regarding major shareholder notification and announcement no. 12 dated 26 March 2015 regarding exercise of the overallotment option in connection with the initial public offering of shares in NNIT A/S (the "Overallotment Option"), NNIT A/S ("NNIT") hereby announces the receipt of the following notification pursuant to Section 29 of the Danish Securities Trading Act regarding Novo Nordisk A/S ("Novo Nordisk"), Novo A/S and the Novo Nordisk Foundation's respective direct and indirect holdings of shares in NNIT.

 

In connection with the exercise of the Overallotment Option, the 1,500,000 NNIT shares of a nominal value of DKK 10 each lent by Novo Nordisk to Danske Bank A/S and Morgan Stanley & Co. International plc on behalf of the managers under the stock lending agreement for the purposes of delivery of shares to investors as a result of the Overallotment Option have today, 26 March 2015, been settled.

 

Following settlement of the Overallotment Option, Novo Nordisk has a direct holding of shares in NNIT of 6,375,000 shares in total of a nominal value of DKK 10 each, corresponding to 25.5% of the share capital and 25.5% of the voting rights in NNIT.

 

Novo Nordisk is a public limited company organised under the laws of Denmark under CVR no. 24 25 67 90. Novo A/S is the parent company of Novo Nordisk through its ownership of 26.46% of the total share capital and 73.97% of all votes in Novo Nordisk. Novo A/S is a public limited company organised under the laws of Denmark under CVR no. 24 25 76 30.

 

Following settlement of the Overallotment Option, Novo A/S has a direct and indirect holding through Novo Nordisk of shares in NNIT of 12,750,000 shares in total of a nominal value of DKK 10 each, corresponding to 51% of the share capital and 51% of the voting rights in NNIT.

Novo A/S is wholly-owned by the Novo Nordisk Foundation. The Novo Nordisk Foundation is a foundation organised under the laws of Denmark under CVR no. 10 58 29 89.

 

About NNIT

NNIT A/S is one of Denmark's leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of 31 December 2014, NNIT A/S had more than 2,400 employees.

For more information please visit www.nnit.com.

Enquiries

Media contacts:

Robert Neimanas, Head of Communications: +45 3079 7480, [email protected]

 

Investor contacts:

Jesper Wagener, Head of Investor Relations: +45 3075 5392, [email protected]

Copyright GlobeNewswire

Attachment(s)
http://hugin.info/163771/R/1906307/678631.pdf

Regulatory News
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire


[HUG#1906307]